Education
About Us
Working with TipRanks
Follow Us
Radiopharm Theranostics Limited Sponsored ADR (RADX)
:RADX
RADX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.08 - $50.82
Previous CloseN/A
Volume12.21K
Average Volume (3M)19.80K
Market Cap
$34.08M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Sep 25, 2025EPS Estimate
-1.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding7,883,165
10 Day Avg. Volume17,743
30 Day Avg. Volume19,802
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Radiopharm Theranostics Limited Sponsored ADR News
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe Data Safety Monitoring Committee concluded that the Phase I trial of Lu-177-RAD204 can proceed to the next dose level, indicating positive clinical progress.
PartnershipsRadiopharm has secured partnerships with leaders in the space such as Lantheus, which owns 12% of the company, and MD Anderson.
Bears Say
Capital MarketsThe analyst has adjusted the price target to reflect a challenging capital markets environment, which may impact future valuations.
Market ValuationThe market is perceived to be dramatically undervaluing the opportunity presented by RADX's diverse radiopharmaceutical pipeline.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
4.35% Other Institutional Investors
95.65% Public Companies and
Individual Investors
RADX FAQ
What was Radiopharm Theranostics Limited Sponsored ADR’s price range in the past 12 months?
Radiopharm Theranostics Limited Sponsored ADR lowest stock price was $3.08 and its highest was $50.82 in the past 12 months.
What is Radiopharm Theranostics Limited Sponsored ADR’s market cap?
Radiopharm Theranostics Limited Sponsored ADR’s market cap is $34.08M.
When is Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date?
Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date is Sep 25, 2025 which is in 71 days.
How were Radiopharm Theranostics Limited Sponsored ADR’s earnings last quarter?
Currently, no data Available
Is Radiopharm Theranostics Limited Sponsored ADR overvalued?
According to Wall Street analysts Radiopharm Theranostics Limited Sponsored ADR’s price is currently Overvalued.
Does Radiopharm Theranostics Limited Sponsored ADR pay dividends?
Radiopharm Theranostics Limited Sponsored ADR does not currently pay dividends.
What is Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate?
Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate is -1.94.
How many shares outstanding does Radiopharm Theranostics Limited Sponsored ADR have?
Radiopharm Theranostics Limited Sponsored ADR has 7,883,165 shares outstanding.
What happened to Radiopharm Theranostics Limited Sponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Radiopharm Theranostics Limited Sponsored ADR?
Currently, no hedge funds are holding shares in RADX
Radiopharm Theranostics Limited Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-111.73%
Trailing 12-Months
Asset Growth
32.54%
Trailing 12-Months
Company Description
Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Technical Analysis
Atara Biotherapeutics
―
NRX Pharmaceuticals
―
Reviva Pharmaceuticals Holdings
―
LakeShore Biopharma
―
RenovoRx
―